肝炎等克服政策研究事業
（○：委員長）
| ○ | 脇田 隆字 | 国立感染症研究所・所長 | |
| ウイルス学、肝炎ウイルス学 | |||
| Wakita T, T Pietschmann, T Kato, T Date, M Miyamoto, Z Zhao, K Murthy, A Habermann, H-G Kräusslich, M Mizokami, R Bartenschlager, T J Liang. Production of Infectious Hepatitis C Virus in Tissue Culture from a Cloned Viral Genome. Nat Med. 2005 11:791-6. | |||
| Wakita T and Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxy-nucleotides: In vitro model for selection of target sequence. J Biol Chem. 1994 269:14205-10 | |||
| Wakita T, Kakumu S, Shibayama M, Yoshioka K, Ito Y, Shinagawa T, Ishikawa T, Takayanagi M, Morishima T. Detection of pre-C and core region mutants of hepatitis B virus in chronic hepatitis B virus carriers. J Clin Invest. 1991 88: 1793-801 | |||
| 相澤 好治 | 北里大学・名誉教授 | ||||
| 予防医学 | |||||
| Aizawa Y, Kudo Y. Magnetometric evaluation of toxicities of chemicals to the lungs and cells.Environ Health Prev Med. 2010 Jul;15(4):197-202. (Epub 2010 Apr 6.) |
|||||
| Wada K, Yoshikawa T, Hayashi T, Aizawa Y. Emergency response technical work at Fukushima Dai-ichi nuclear power plant: occupational health challenges posed by the nuclear disaster. Occup Environ Med 2012.8, 69(8):599-602. Epub 2012 Apr 12. | |||||
| Kido T, Sugaya C, Ikeuchi R, Kudo Y, Tsunoda M, Aizawa Y. The increases in mRNA expressions of inflammatory cytokines by adding cleaning solvent or tetrachloroethylene in the murine macrophage cell line J774.1 evaluated by real-time PCR. Ind Health. 2013;51(3):319-25. Epub 2013 Mar 29. | |||||
| 青栁 豊 | 新潟医療センター・消化器内科部長 | ||
| 消化器内科 | |||
| Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, and Ichida F. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer, 61:769-774, 1988. | |||
| Aoyagi Y, Saitoh A, Suzuki Y, Igarashi K, Oguro M, Yokota T, Mori S, Suda T, Isemura M, and Asakura, H. Fucosylation index of alpha-fetoprotein, a possible aid in early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology, 17:50-52, 1993. | |||
| Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H, Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer, 83:2076-2082, 1998. | |||
| 石橋 大海 | 社会福祉法人 高邦福祉会 柳川療育センター・施設長、国際医療福祉大学 名誉教授 | ||||
| 消化器病学（肝臓学） | |||||
| Liver architecture, cell function, and disease. (Ishibashi H, Nakamura M, Komori A, Migita K, Shimoda S. Semin Immunopathol. 2009 Sep;31(3):399-409.) |
|||||
| Risk factors and prediction of long-term outcome in primary biliary cirrhosis. (Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Intern Med. 2011;50(1):1-10.) | |||||
| Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. (Nakamura M, Nishida N, Kawashima M, Aiba Y, Mizokami M, Nakanuma Y, Tokunaga K, Ishibashi H. et al. (Am J Hum Genet. 2012 Oct 5;91(4):721-728.) | |||||
| 梅田 勝 | 東京工科大学 副学長 | ||||
| 衛生行政、公衆衛生 | |||||
| 梅田 勝、松浦 賢長、小林 臻、吉武 克宏、松尾 準雄、平山 宗宏：先天性心疾患の発見の機会に関する研究． 小児保健研究，Vol.49(4):pp.471-476,1990 | |||||
| 梅田 勝、松浦 賢長、小林 臻、吉武 克宏、松尾 準雄、平山 宗宏：先天性心疾患児の出生と母親の出産年齢との関係に関する研究． 小児保健研究，Vol.49(4):pp.467-470,1990 | |||||
| 梅田 勝、松浦 賢長、稲田 靖二、吉武 克宏、松尾 準雄、平山 宗宏：心疾患児の学校における運動・生活管理に関する研究． 小児保健研究，Vol.50(1):pp.37-41,1991 | |||||
| 樋野 興夫 | 順天堂大学 名誉教授 | ||||
| 病理学・発がん | |||||
| Hino O., Kitagawa T. and Sugano H.: Relationship between serum and histochemical markers for hepatitis B virus and rate of viral integration in hepatocellular carcinomas in Japan. Int J Cancer 35: 5-10, 1985 | |||||
| Hino O., Shows T. B. and Rogler C. E.: Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation. Proc Natl Acad Sci U S A 83: 8338-8342, 1986 | |||||
| Hino O., Tabata S. and Hotta Y.: Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A 88: 9248-9252, 1991 | |||||
| 宮村 達男 | 国立感染症研究所・名誉所員 | ||||
| ウイルス学 | |||||
| An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Kuo,G., Choo,Q-L., Alter,H.J., Gitnick,G.L., Redeker,A.G., Purcell,R.H., Miyamura,T. Dienstag J.L., Alter,M.J., Stevens,C.E., Tegtmeier,G.E., Bonino,F., Colombo,M., Lee,W-S., Kuo,C., Berger,K., Shuster,J.R., Overby,L.R., Bradley,D.W., and Houghton,M. Science 244: 362-364, 1989. | |||||
| Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: Application to diagnosis and blood screening for post transfusion hepatitis. Miyamura,T., Saito,I., Katayama,T., Kikuchi,S., Tateda,A., Houghton,M., Choo,Q-L., and Kuo,G. Proc.Natl.Acad.Sci.USA, 87: 983-987, 1990. | |||||
| A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Kubo,Y., Takeuchi,K., Boonmar,S., Katayama,T., Choo,Q-L., Kuo,G., Weiner,A.W., Bradley,D.W., Houghton,M., Saito,I., and Miyamura,T. Nucl.Acids Res. 17:10367-10372, 1989. | |||||
| 藤元治朗 | 公益財団法人大阪国際がん治療財団・大阪重粒子線センター センター長、兵庫医科大学名誉教授 | ||
| 肝胆膵外科 | |||
| Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5: 226-230, 1999 |
|||
| Kosaka H, Yoshimoto T, Yoshimoto T, Fujimoto J, Nakanishi K: Interferon-γis a therapeutic molecule for prevention of postoperative adhesion formation. Nat Med 14: 437- 441, 2008 | |||
| Takahashi H, Fujimoto J, Hanada S, Isselbacher K. (T.H. & J.F. jointly as First Author): Acute hepatitis in rats expressing human hepatitis B virus transgenes. Proc Natl Acad Sci USA 92: 1470-74, 1995 |
|||
| 大石 和徳 | 富山県衛生研究所・所長 | ||
| 肺炎球菌感染症、COVID-19、ワクチン | |||
| Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013–2019. Tamura K, Chang B, Shimbashi R, Watanabe H, Tanabe Y, Kuronuma K, Oshima K, Maruyama T, Fujita J, Abe S, Kasahara K, Nishi J, Kubota T, Kinjo Y, Fujikura H, Fukusumi M, Shimada T, Sunagawa T, Suzuki M, Yamamoto Y, Oishi K. Vaccine 40:3338-44, 2022 |
|||
| Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥65 years: comparison of booster effects based on intervals of 0.5 and 1.0 year. Azuma M, Oishi K, Akeda Y, Morino S, Motoki Y, Hanibuchi M, Nishioka Y. Vaccine 41:1042-9,2023. | |||
| Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Itamochi M, Yazawa S, Inasaki N, Saga Y, Yamazaki E, Shimada T, Tamura K , Maenishi E , Isobe J , Nakamura M, Takaoka M , Sasajima H, Kawashiri C, Tani H, Oishi K. Vaccine 41:2234-42,2023 |
|||
